Adele Oliva

Adele is a graduate of Saint Joseph's University and has an MBA from Cornell University, where she was awarded a Fried Fellowship. Adele is a Founder and on the Steering Committee of the Private Equity Women’s Investor Network (PEWIN).

Adele Oliva has been a healthcare investor for over 20 years and focuses on commercial stage medical technology, healthcare service, and specialty therapeutic investments. Adele co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing and the firm has since raised two funds and has over $900 million under management. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997. Forbes recognized Adele on its Midas List of top 100 technology investors worldwide and top 10 life science investors. Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Genoptix (acquired by NeoGenomics), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan) and TELA Bio. She currently serves on the boards of 3B Scientific, Colorescience, Greenbrook TMS, Homestead Smart Health Plans, Innovative Health, miraDry, Onkos Surgical and St. Joseph's University.

Adele is a member of Kauffman Fellows Class 3 and served her fellowship under mentor Janet Effland at Apax Partners (formerly Patricof & Co.) in Menlo Park, CA. She was also a mentor for Class 14 member Sanjay Mistry.